Tempest Therapeutics Announces Up To $6 Million Private Placement

$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrantsBRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or ...